Loading…
XTL Biopharmaceuticals Ltd. is projected to rise to $3.24 by 2027, a +33% move from its current price of $2.44. XTLB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.31 | $2.44 | $2.57 | -0.11% |
| May 30 | $2.26 | $2.43 | $2.63 | -0.21% |
| May 31 | $2.22 | $2.43 | $2.67 | -0.32% |
| Jun 1 | $2.18 | $2.43 | $2.71 | -0.42% |
| Jun 2 | $2.15 | $2.43 | $2.74 | -0.53% |
| Jun 3 | $2.12 | $2.42 | $2.77 | -0.63% |
| Jun 4 | $2.10 | $2.42 | $2.79 | -0.74% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.10 | $2.42 | $2.79 | -0.74% |
| Week 2 | $1.96 | $2.40 | $2.94 | -1.47% |
| Week 3 | $1.86 | $2.39 | $3.06 | -2.19% |
| Week 4 | $1.78 | $2.37 | $3.15 | -2.91% |
| Week 5 | $1.71 | $2.35 | $3.24 | -3.63% |
| Week 6 | $1.64 | $2.33 | $3.31 | -4.34% |
| Week 7 | $1.59 | $2.32 | $3.38 | -5.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
XTL Biopharmaceuticals Ltd. is a biopharmaceutical company that engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.
The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
XTL Biopharmaceuticals Ltd. trades under the symbol XTLB and is categorized in the Healthcare sector. The current price is $2.51, and the market capitalization is $5.94M, with a rank of 5296.
The price outlook is mixed in the near term but turns more clearly bullish in later years according to the provided forecast. The 2026 average price is $2.51, with a neutral sentiment, while the 2027–2050 forecasts show rising averages and positive ROI, culminating in a 2050 average of $10.38 and a maximum of $23.88 with a 313.6% ROI.
A major floor 47.5% below — a decisive break under it would weaken the trend.
The nearest floor, 5.7% below — buyers have tended to step in here.
The nearest ceiling, 59.8% above — a clean break opens room to run.
A major ceiling 83.6% above — clearing it would confirm fresh momentum.
Key XTLB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XTLB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.48 | Sell | $2.48 | Sell |
| MA 10 | $2.57 | Sell | $2.57 | Sell |
| MA 20 | $2.91 | Sell | $2.66 | Sell |
| MA 50 | $2.63 | Sell | $2.75 | Sell |
| MA 100 | $2.98 | Sell | $3.01 | Sell |
| MA 200 | $3.70 | Sell | $3.62 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.58 | Neutral |
| Stoch RSI (14) | 21.31 | Neutral |
| CCI (20) | -71.16 | Neutral |
| Williams %R (14) | -87.23 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -3.94 | Sell |
| Bollinger %B (20,2) | 0.27 | Neutral |
| Stochastic %K (14) | 12.77 | Buy |
| TRIX (15) | -0.07 | Sell |
| Awesome (5,34) | -0.23 | Sell |
| Ultimate (7,14,28) | 36.17 | Neutral |
| Momentum (10) | -0.17 | Sell |
| Aroon Osc (25) | 8.00 | Buy |
| Hull MA (9) | 2.40 | Buy |
| ADX (14) | 14.22 | Neutral |
| ATR (14) | 0.15 | Info |
The 30-day technical picture is bearish. The RSI(14) is 40, while the SMA50 is $2.63 and the SMA200 is $3.73, signaling potential resistance above the current level.
Near-term support sits at $2.30 and resistance at $3.90, with a 30-day price range of $1.73 to $3.64. The stock shows elevated volatility, listed at 100% annualized volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.30 | $2.44 | $4.17 | 0% | Neutral | |
| $2.33 | $3.24 | $4.87 | +33% | Bullish | |
| $2.51 | $3.69 | $5.91 | +51% | Bullish | |
| $2.34 | $3.63 | $6.08 | +49% | Bullish | |
| $2.01 | $3.27 | $5.69 | +34% | Bullish | |
| $1.80 | $3.07 | $5.53 | +26% | Bullish | |
| $1.58 | $2.80 | $5.21 | +15% | Neutral | |
| $1.94 | $3.58 | $6.83 | +47% | Bullish | |
| $2.36 | $4.54 | $8.88 | +86% | Bullish | |
| $2.31 | $4.62 | $9.25 | +89% | Bullish | |
| $1.99 | $4.42 | $9.73 | +81% | Bullish | |
| $4.48 | $9.96 | $22.90 | +308% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.30 | $2.44 | $2.88 | +0.00% |
| June 2026 | $1.87 | $2.24 | $2.78 | -8.28% |
| July 2026 | $1.82 | $2.22 | $2.82 | -0.97% |
| August 2026 | $2.02 | $2.49 | $3.24 | +12.42% |
| September 2026 | $2.09 | $2.61 | $3.44 | +4.73% |
| October 2026 | $2.05 | $2.59 | $3.47 | -0.76% |
| November 2026 | $2.20 | $2.80 | $3.79 | +8.15% |
| December 2026 | $2.37 | $3.04 | $4.17 | +8.72% |
Click any year to see its month-by-month XTLB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The XTLB price prediction for 2026 points to an average of $2.44 (low $2.30, high $4.17) — a potential gain of 0% on today's $2.44. A consolidation phase looks the most probable path here.
In 2027, XTLB is projected to trade between $2.33 and $4.87, averaging $3.24 — a potential gain of +33% from today's $2.44. That is up +33% on the projected 2026 average. Momentum favours further upside here.
XTL Biopharmaceuticals Ltd.'s 2028 outlook centres on $3.69, within a $2.51 to $5.91 range. That is up +14% on the projected 2027 average. That marks a +51% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, XTLB could reach as high as $6.08, with a base case around $3.63 and support toward $2.34 — roughly +49% from $2.44. Momentum favours further upside here.
Expect XTLB to range from $2.01 to $5.69 through 2030. The $3.27 average target implies a +34% move from current prices. That is -10% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
The XTLB price prediction for 2031 points to an average of $3.07 (low $1.80, high $5.53) — a potential gain of +26% on today's $2.44. Momentum favours further upside here.
In 2032, XTLB is projected to trade between $1.58 and $5.21, averaging $2.80 — a potential gain of +15% from today's $2.44. That is -9% versus the projected 2031 average. A consolidation phase looks the most probable path here.
XTL Biopharmaceuticals Ltd.'s 2033 outlook centres on $3.58, within a $1.94 to $6.83 range. That is up +28% on the projected 2032 average. That marks a +47% change versus current levels. Momentum favours further upside here.
By 2034, XTLB could reach as high as $8.88, with a base case around $4.54 and support toward $2.36 — roughly +86% from $2.44. Buyers look set to stay in control over this stretch.
Expect XTLB to range from $2.31 to $9.25 through 2035. The $4.62 average target implies a +89% move from current prices. That is up +2% on the projected 2034 average. Momentum favours further upside here.
The XTLB price prediction for 2040 points to an average of $4.42 (low $1.99, high $9.73) — a potential gain of +81% on today's $2.44. Buyers look set to stay in control over this stretch.
In 2050, XTLB is projected to trade between $4.48 and $22.90, averaging $9.96 — a potential gain of +308% from today's $2.44. That is up +125% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in XTLB today (≈ 409.836066 XTLB) could be worth
$4,080.56
+$3,080.56 (+308%) by 2050 · US Dollar
Based on the average projected XTLB price of $9.96 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in XTLBwould be worth at today's price.
$1,000 invested in XTLB on May 27, 2025 (≈ 221.238939 XTLB) would be worth
$539.82
-$460.18 (-46.0%) today · 0.54× · US Dollar
Based on a XTLB entry price of $4.52 vs. today's $2.44.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.57 | $949.42 | -5.1% |
| 1 month ago | $2.39 | $1,020.92 | +2.1% |
| 3 months ago | $3.04 | $802.63 | -19.7% |
| 6 months ago | $3.32 | $734.94 | -26.5% |
| 1 year ago | $4.52 | $539.82 | -46.0% |
| All time (5.0y) ago | $14.16 | $172.32 | -82.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our XTLB forecast.
Our base-case forecast reaches $4.90 around 2050.
Implied market cap at $4.90: $11.59M
The multi-year forecast depicts a bullish trajectory after 2026, with notable gains in several years. In 2027, the average is $3.33 with a 32.5% ROI and a bullish sentiment; in 2028, the average is $3.91 with a 55.7% ROI; in 2029, the average is $3.81 with a 51.7% ROI; and in 2030, the average is $3.35 with a 33.5% ROI. The 2031–2032 stretch shows continued upside with 2031 at $3.21 (27.9% ROI) and 2032 at $2.89 (15% ROI).
The 2033–2035 period remains bullish with 2033 at $3.68 (46.6% ROI), 2034 at $4.79 (91% ROI), and 2035 at $4.80 (91.3% ROI).
Beyond 2035, the forecast continues to project gains, with 2040 averaging $4.64 (84.9% ROI) and 2050 averaging $10.38 (313.6% ROI) and a maximum of $23.88, all labeled bullish. These figures underpin a prolonged upside potential, though they are estimates and not guarantees; actual results will depend on a range of factors including drug development progress, regulatory outcomes, and market dynamics.
Tap a question to reveal the answer.
In 2030, the forecast shows a minimum of $2.06, an average of $3.35, and a maximum of $5.85, with an estimated ROI of 33.5% and a bullish sentiment.
The long-range outlook shows several bullish years with positive ROI (e.g., 32.5% in 2027, 55.7% in 2028, up to 313.6% in 2050). However, 2026 is neutral with 0% ROI, and these are estimates, not guarantees.
Yes. The 2050 forecast shows an average price of $10.38 and a maximum of $23.88, with a ROI of 313.6% and bullish sentiment.
Current price is $2.51 and market cap is $5.94M.
The 30-day picture is bearish with RSI(14) at 40. The SMA50 is $2.63 and the SMA200 is $3.73. Support is at $2.30 and resistance at $3.90, and the 30-day range spans $1.73 to $3.64.
XTL Biopharmaceuticals Ltd. Community Discussion
0Share your XTL Biopharmaceuticals Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.